Search

Your search keyword '"Kavadichanda, Cg"' showing total 2 results
Start Over Author "Kavadichanda, Cg" Topic covid-19
2 results on '"Kavadichanda, Cg"'

1. Higher risk of short term COVID-19 vaccine adverse events in myositis patients with autoimmune comorbidities: results from the COVAD study.

Author

Dey M, R N, Nikiphorou E, Sen P, Saha S, Lilleker JB, Agarwal V, Kardes S, Day J, Milchert M, Joshi M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, Selva O'Callaghan A, Kim M, Chatterjee T, Tan AL, Makol A, Nune A, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Kuwana M, Distler O, Barman B, Singh YP, Ranjan R, Jain A, Pandya SC, Pilania RK, Sharma A, Manoj MM, Gupta V, Kavadichanda CG, Patro PS, Ajmani S, Phatak S, Goswami RP, Chowdhury AC, Mathew AJ, Shenoy P, Asranna A, Bommakanti KT, Shukla A, Pande AR, Chandwar K, Pauling JD, Wincup C, Üsküdar Cansu D, Zamora Tehozol EA, Rojas Serrano J, García-De La Torre I, Del Papa N, Sambataro G, Fabiola A, Govoni M, Parisi S, Bartoloni Bocci E, Sebastiani GD, Fusaro E, Sebastiani M, Quartuccio L, Franceschini F, Sainaghi PP, Orsolini G, De Angelis R, Danielli MG, Venerito V, Traboco LS, Hoff LS, Kusumo Wibowo SA, Tomaras S, Langguth D, Limaye V, Needham M, Srivastav N, Yoshida A, Nakashima R, Sato S, Kimura N, Kaneko Y, Loarce-Martos J, Prieto-González S, Gil-Vila A, Gonzalez RA, Chinoy H, Agarwal V, Aggarwal R, and Gupta L

Subjects
Humans, COVID-19 Vaccines, Vaccination, COVID-19, Myositis, Autoimmune Diseases
Published
2023
Full Text
View/download PDF

2. COVID-19 Vaccination In Autoimmune Diseases (COVAD) Study: Vaccine Safety In Idiopathic Inflammatory Myopathies

Author

Gil‐vila, A, Naveen, R, Selva‐o'Callaghan, A, Sen, P, Nune, A, Gaur, Ps, Gonzalez, Ra, Lilleker, Jb, Joshi, M, Agarwal, V, Kardes, S, Kim, M, Day, J, Makol, A, Milchert, M, Gheita, T, Salim, B, Velikova, T, Gracia‐ramos, Ae, Parodis, I, Nikiphorou, E, Tan, Al, Chatterjee, T, Cavagna, L, Saavedra, Ma, Shinjo, S, Katsuyuki, Zn, Knitza, J, Kuwana, M, Distler, O, Chinoy, H, Aggarwal, R, Gupta, L, Barman, B, Singh, Yp, Ranjan, R, Jain, A, Pandya, Sc, Pilania, Rk, Sharma, A, Manesh, Mm, Gupta, V, Kavadichanda, Cg, Patro, Ps, Ajmani, S, Phatak, S, Goswami, Rp, Chowdhury, Ac, Mathew, Aj, Shenoy, P, Asranna, A, Bommakanti, Kt, Shukla, A, Pandey, Akr, Chandwar, K, Cansu, Dü, Pauling, Jd, Wincup, C, Del Papa, N, Sambataro, G, Atzeni, F, Govoni, M, Parisi, S, Bocci Bartoloni, E, Sebastiani, Gd, Fusaro, E, Sebastiani, M, Quartuccio, L, Franceschini, F, Sainaghi, Pp, Orsolini, G, De Angelis, R, Danielli, Mg, Venerito, V, Traboco, Ls, Wibowo, Sak, Tehozol, Eaz, Serrano, Jr, García‐De La Torre, I, Loarce‐martos, J, Prieto‐gonzález, S, Yoshida, A, Nakashima, R, Sato, S, Kimura, N, Kaneko, Y, Tomaras, S, Gromova, Ma, Aharonov, Om, Hmamouchi, I, Hoff, Ls, Giannini, M, Maurier, F, Campagne, J, Meyer, A, Nagy‐vincze, M, Langguth, D, Limaye, V, Needham, M, Srivastav, N, Hudson, M, Landon‐cardinal, O, Shaharir, Ss, Zuleta, Wgr, Silva, Jap, Fonseca, Je, Zimba, O, Institut Català de la Salut, [Gil-Vila A, Selva-O'Callaghan A] Unitat d’Inflamació i Autoimmunitat, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Ravichandran N] Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. [Sen P] Maulana Azad Medical College, Delhi, India. [Nune A] Southport and Ormskirk Hospital NHS Trust, Southport, UK. [Gaur PS] Smt. Kashibai Navale Medical and General Hospital, Pune, India, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Adult, Male, COVID-19 Vaccines, dermatomyositis, Physiology, Simian Acquired Immunodeficiency Syndrome, rheumatology, Keywords: COVID-19, Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores], Autoimmune Diseases, Myositis, Inclusion Body, Cellular and Molecular Neuroscience, Physiology (medical), Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunotherapy, Active::Vaccination [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Other subheadings::Other subheadings::/adverse effects [Other subheadings], virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Animals, Humans, BNT162 Vaccine, enfermedades musculoesqueléticas::enfermedades musculares::miositis [ENFERMEDADES], Malalties autoimmunitàries, Immune System Diseases::Autoimmune Diseases [DISEASES], enfermedades del sistema inmune::enfermedades autoinmunes [ENFERMEDADES], COVID-19, Immunoglobulins, Intravenous, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], myositis, vaccination, Exanthema, Musculoskeletal Diseases::Muscular Diseases::Myositis [DISEASES], Inflamació, terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunoterapia activa::vacunación [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Female, Neurology (clinical), COVID-19 (Malaltia) - Vacunació, Hydroxychloroquine
Abstract

COVID-19; Dermatomyositis; Vaccination COVID-19; Dermatomiositis; Vacunación COVID-19; Dermatomiositis; Vacunació Introduction/Aims In this study we investigated COVID-19 vaccination–related adverse events (ADEs) 7 days postvaccination in patients with idiopathic inflammatory myopathies (IIMs) and other systemic autoimmune and inflammatory disorders (SAIDs). Methods Seven-day vaccine ADEs were collected in an international patient self-reported e-survey. Descriptive statistics were obtained and multivariable regression was performed. Results Ten thousand nine hundred respondents were analyzed (1227 IIM cases, 4640 SAID cases, and 5033 healthy controls [HCs]; median age, 42 [interquartile range, 30-455] years; 74% female; 45% Caucasian; 69% completely vaccinated). Major ADEs were reported by 76.3% of the IIM patients and 4.6% reported major ADEs. Patients with active IIMs reported more frequent major (odds ratio [OR], 2.7; interquartile range [IQR], 1.04-7.3) and minor (OR, 1.5; IQR, 1.1-2.2) ADEs than patients with inactive IIMs. Rashes were more frequent in IIMs (OR, 2.3; IQR, 1.2-4.2) than HCs. ADEs were not impacted by steroid dose, although hydroxychloroquine and intravenous/subcutaneous immunoglobulins were associated with a higher risk of minor ADEs (OR, 1.9; IQR, 1.1-3.3; and OR, 2.2; IQR, 1.1-4.3, respectively). Overall, ADEs were less frequent in inclusion-body myositis (IBM) and BNT162b2 (Pfizer) vaccine recipients. Discussion Seven-day postvaccination ADEs were comparable in patients with IIMs, SAIDs, and HCs, except for a higher risk of rash in IIMs. Patients with dermatomyositis with active disease may be at higher risk, and IBM patients may be at lower risk of specific ADEs. Overall, the benefit of preventing severe COVID-19 through vaccination likely outweighs the risk of vaccine-related ADEs. Our results may inform future guidelines regarding COVID-19 vaccination in patients with SAIDs, specifically in those with IIMs. Studies to evaluate long-term outcomes and disease flares are needed to shed more light on developing future COVID-19 vaccination guidelines. National Institution for Health Research Manchester Biomedical Research Centre (to H.C.).

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results